Recursion said it now expects its cash burn to be less than $450 million in 2025 and less than $390 million in 2026, excluding severance costs of income received by the company from collaborations ...

REC-1245 was developed using Recursion's end-to-end workflow, making results from this program more meaningful. REC-3565: Developed for relapsed refractory B-cell malignancies.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading higher and trending. The company on Tuesday announced a reduction in personnel and infrastructure aimed at extending its cash runway.

In an effort to save costs and make its financial resources last longer, Recursion Pharmaceuticals (RXRX 0.70%) is slimming down and streamlining. After the biotech updated its strategy to do so ...

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) continues to have a pipeline of drugs that might provide further validation for the company's platform, but recent updates were not a roaring success.

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a ...

Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday June 10, 2025 — 04:35 pm EDT Written by Eric Volkman for The Motley Fool -> ...

There comes a time in any software developer’s life when they look at their achievements, the lines of code written and the ...

Recently, two leading and long-established firms in the expanding AI drug discovery sector revealed an unexpected merger. In an approximate 75-25 agreement, Recursion Bio and Exscientia are set to ...

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 GlobeNewswire Apr 22, 2025, 5:34:17 PM ...